Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
302.24 K
Value Traded
-
Short % Float
-
Days to Cover
1.0
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.11 B
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
51.72 M
Float Shares
-
Insiders
-
Institutions
11.70%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CTY Catalyst Timeline
Dated clinical, regulatory and corporate events for City Therapeutics, Inc. Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for City Therapeutics, Inc. Common Stock
3Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How CTY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every CTY program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| NELSEN ROBERTDirector, 10% Owner | Buy | 170,000 13,692,507 held | $18.00 | 10/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CTY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CTY for Q2 2026. | ||||
CTY Institutional Ownership Trends
CTY Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
21.3K
Shares Sold Short
-65.5% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
45.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CTY ranks across every disease it competes in
Competitive Position is a premium feature
See how CTY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCTY News
-CTY
Oct 19, 2026▼ -3.4%today
City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
City Therapeutics has announced the successful closing of its upsized initial public offering, raising approximately $230 million. The offering consisted of 12,777,777 shares priced at $18.00 each, including additional shares purchased by underwriters. The company's stock began trading on the Nasdaq Global Market under the ticker symbol CTY on October 16, 2026.
Read more →-CTY
Oct 16, 2026▼ -3.4%today
City Therapeutics Announces Pricing of Upsized Initial Public Offering
City Therapeutics, a clinical-stage biotechnology company, has announced the pricing of its upsized initial public offering, offering 11,111,111 shares at $18.00 each. The gross proceeds are projected to be around $200 million. The stock will start trading on the Nasdaq Global Market under the ticker CTY on October 16, 2026.
Read more →About City Therapeutics, Inc. Common Stock
BIOPHARMAWATCH ELITE PLUS
Trade the next CTY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime